Several pharmaceutical companies declared bankruptcy.

Pharmaceutical Network October 19 this year, a number of pharmaceutical companies declared bankruptcy, some industry insiders said that the actual figure may be much larger than the announced situation.
1, so far, more than 10 pharmaceutical companies declared bankruptcy according to Saibai Blue incomplete combing, the opening year so far, more than 10 pharmaceutical companies declared bankruptcy.
, Yunnan Biopharmaceutical Co., Ltd., a subsidiary of Haizheng Pharmaceuticals, filed an application for bankruptcy restructuring with the People's Court.
Haizheng Pharmaceuticals said that through the restructuring process, the introduction of strategic investors with financial strength, management experience and other advantages, improve Yunsheng's asset-liability structure, accelerate the remodeling of enterprise development strategy, seize the opportunities brought about by the development of the industry.
In addition to Haizheng Pharmaceuticals, according to Cypress Blue incomplete combing, this year declared bankruptcy of pharmaceutical companies are: Sichuan Chunyu Pharmaceuticals, Yuheng Pharmaceuticals and Xinbang Pharmaceuticals, two listed pharmaceutical companies of the majority shareholder Yu Heng Group, Hebei Fuge Pharmaceutical Co., Ltd., Tianjin Children's Pharmaceuticals, Suzhou Hongjian Biotechnology Co., Ltd., Jiangsu Xinfukang Biotech Co., Ltd., Guangzhou Pharmaceutical Economic Development Co., Ltd. Yuexiu District Chinese Medicine Management Department, Ningxia Pharmaceutical Business (Group) Co., Ltd. and its 9 subsidiaries, Foshan Huayi Pharmaceutical Trading Co., Ltd., Chongqing Natural Pharmaceutical Co., Ltd., Zhejiang Shuangxi Pharmaceutical Co., Ltd., Yunnan Tengyao Biotechnology Co., Ltd.
a general view, the pharmaceutical enterprises declared bankrupt include both Chinese medicine processing enterprises and chemical pharmaceutical enterprises, both pharmaceutical industry enterprises, as well as pharmaceutical commercial companies, and mainly pharmaceutical commercial enterprises.
The main reasons for the bankruptcy of the above-mentioned enterprises are broken capital chain, poor management, inability to pay off debts due, and insufficient assets to pay off all debts, failure to pay off debts due, and a clear lack of solvency, because of the refusal to perform labor contract disputes with employees, the court was listed as dishonest blacklist, unable to continue to operate.
also showed that 35 companies closed in the health care sector last year, with 22 filings for bankruptcy, mainly in the Internet medical and pharmaceutical distribution companies.
as to the reasons for the collapse, there are mainly market positioning problems, capital problems and external factors.
On this industry phenomenon, Shengshan Asset Executive Director Yu Yichao told Cypress today that this year's Chinese pharmaceutical market is a two-day ice fire, the "28" law is being more and more obvious, that is, 20% of enterprises concentrated 80% of the resources.
On the one hand, the first and second-tier market head biopharmaceutical enterprises are sought after: the total market value of the pharmaceutical sector increased from 2 trillion yuan in 2015 to 8 trillion yuan in 2020, 100 billion market club pharmaceutical companies reached 12, Hong Kong stocks newly listed biopharmaceutical enterprises more than 20, the first half of the top 20 Ninety-nine of the funds were pharmaceutical-themed funds with a maximum increase of 90%, and A-shares raised 39.4 billion yuan (second only to the semiconductor sector) in IPO of 26 biopharmaceutical companies in January-August 2020.
the other hand, many pharmaceutical companies, especially small pharmaceutical distributors, have gone bankrupt under the influence of various policies to bring volume procurement, health care catalog reform and promote the rapid entry of new drugs from overseas into the Chinese market.
new policies, new technologies and new markets are changing rapidly, it is not surprising to accelerate change and accelerate differentiation.
pharmaceutical industry has begun and will accelerate the evolution from "scatter" to "poly", from "small" to "big", from "imitation" to "creation".
pharmaceutical companies need to pay more attention to innovation and barriers in the future, group heating, mergers and acquisitions and integration will be the norm.
2, at this stage, the pressure of small and medium-sized drug companies obviously on a number of pharmaceutical enterprises bankruptcy phenomenon, a domestic pharmaceutical company executive who did not want to be named revealed to Cypress Blue, according to his understanding of the actual number of bankrupt enterprises may be much larger than the known situation, and bankrupt enterprises to small and medium-sized pharmaceutical commercial companies most prominent.
The reason for this is that, unlike pharmaceutical industry enterprises, the debt ratio of pharmaceutical commercial enterprises is relatively high in itself, and the requirements for cash flow are higher, while gross margin is generally performing, so the ability to withstand risk is relatively low.
Under the influence of multiple policies based on volume procurement, the decline in profit margins of pharmaceutical commercial enterprises is obvious, and the large number of hospital drug use problems other than the national collection varieties are still unsolved, which has put a lot of pressure on the cash flow of pharmaceutical commercial enterprises.
research institutions have pointed out that the phenomenon of pharmaceutical group divestiture of the commercial sector analysis pointed out that the pharmaceutical enterprise's business sector gross margin is low, divestiture of the commercial sector, for the enterprise's cash flow, operational quality, asset-liability ratio, etc. have a positive impact.
need to see, with the normalization of the national organization of drug collection, collection in varieties, categories will continue to expand, biological products, Chinese medicine collection news has also been sent out.
, in more varieties, a large number of distributors will also face a contraction in gross margin.
said the above-mentioned people to Seber blue, in some hospital repayment cycle is not optimistic, even there are no shortage of pharmaceutical commercial companies directly by the hospital's delay in the repayment of cases.
compared with the general international level, the number of pharmaceutical commercial companies in China remains high, but the overall strength is not strong, the proportion of head pharmaceutical commercial companies in the market share compared with the international level is still not a small gap.
two-vote system, volume procurement and other policies have the demand to improve the concentration of the pharmaceutical circulation industry, in the process of increasing the concentration of the industry, small and medium-sized pharmaceutical commercial enterprises naturally face the pressure to withdraw.
in the current policy environment, there are industry insiders said that the drug circulation link profit margins have been greatly squeezed, the development of many pharmaceutical circulation enterprises are facing unprecedented challenges.
3, the main business is bad or the core reasons for the pharmaceutical industry enterprises declared bankruptcy, the above-mentioned industry insiders told Cypress Blue, whether it is cash flow problems or inability to repay debt, the core problem is that the business and main business is not good.
, in his view, bankruptcy is a business problem, cash flow problems may be sales problems, sales problems may be behind the product problems.
, the development of the main business continues to show signs of decline is the core reason for the bankruptcy of pharmaceutical companies.
, we must also see that cash flow and the operating status of enterprises are not fully synchronized, different types of pharmaceutical enterprises for cash flow demand situation, financing capacity is also different.
It should be said that for different pharmaceutical enterprises, cash flow cordon is not the same, the overall development of better enterprises, the general financing capacity is also strong, that cordon can be set up a lower.
The above-mentioned person said to Seberan, as a participant in the market economy, the relatively healthy state of pharmaceutical enterprises should be the main business health, cash flow is positive, if the cash flow is negative, once the lending environment continues to be not optimistic, enterprises may face operational risks.
It further stated that for pharmaceutical industry enterprises, the main factors that determine their main business situation are quality and cost - from a quality point of view, if enterprises can not control the quality of products very well, can not guarantee good operation, good management can not guarantee the cash flow of enterprises will naturally have problems;
bankruptcy could mean a retirement on the big stage of the pharmaceutical industry for a single pharmaceutical company.
Although the frequency of plays on this stage is high and low, in general, as the tide comes and goes, the stage does always switch between different protagonists and different plots.
.